Franklin Street Advisors Inc. NC Sells 98,573 Shares of Zoetis Inc. $ZTS

Franklin Street Advisors Inc. NC trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 87.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,200 shares of the company’s stock after selling 98,573 shares during the period. Franklin Street Advisors Inc. NC’s holdings in Zoetis were worth $1,787,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Halbert Hargrove Global Advisors LLC grew its holdings in Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares in the last quarter. Global Wealth Strategies & Associates bought a new stake in shares of Zoetis in the 4th quarter valued at about $25,000. KERR FINANCIAL PLANNING Corp bought a new stake in shares of Zoetis in the 3rd quarter valued at about $31,000. Lodestone Wealth Management LLC bought a new stake in shares of Zoetis in the 4th quarter valued at about $30,000. Finally, Holos Integrated Wealth LLC bought a new stake in shares of Zoetis in the 4th quarter valued at about $32,000. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ZTS shares. Morgan Stanley set a $160.00 price target on shares of Zoetis in a report on Thursday, December 18th. William Blair restated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. HSBC set a $140.00 price target on shares of Zoetis in a report on Wednesday, December 10th. Piper Sandler restated a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Finally, UBS Group set a $136.00 price target on shares of Zoetis in a report on Thursday, January 29th. Six equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Stock Performance

Shares of Zoetis stock opened at $119.66 on Thursday. The firm has a market capitalization of $50.51 billion, a P/E ratio of 19.88, a PEG ratio of 1.80 and a beta of 0.98. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The company has a 50 day moving average price of $122.39 and a 200 day moving average price of $127.49. Zoetis Inc. has a 52 week low of $113.29 and a 52 week high of $172.23.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. Zoetis’s revenue was up 3.0% on a year-over-year basis. During the same period last year, the firm posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.